Sugemalimab as first-line treatment for non-small cell lung cancer:a rapid health technology assessment
10.12173/j.issn.1005-0698.202411051
- VernacularTitle:舒格利单抗一线治疗非小细胞肺癌的快速卫生技术评估
- Author:
Yibing HOU
1
;
Shuo KANG
;
Yuan GONG
;
Xiaohui WANG
;
Ying NIE
;
Huanlong LIU
Author Information
1. 河北医科大学第二医院药学部(石家庄 050000)
- Publication Type:Journal Article
- Keywords:
Sugemalimab;
Non-small cell lung cancer;
Effectiveness;
Safety;
Economics;
Rapid health technology assessment
- From:
Chinese Journal of Pharmacoepidemiology
2025;34(7):806-814
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the efficacy,safety and economy of sugemalimab in the first-line treatment of non-small cell lung cancer(NSCLC)by rapid health technology assessment.Methods PubMed,Cochrane Library,Embase,CNKI,WanFang Data,VIP and official websites of health technology assessment(HTA)institutions were systematically searched to collect HTA reports,systematic reviews/Meta-analysis and pharmacoeconomic studies of sugemalimab in first-line treatment of NSCLC from inception to October 31,2024.Two reviewers independently screened the literature,extracted information and performed quality assessment of the included studies,and then performed descriptive analysis on the results.Results A total of 15 articles were selected,including 4 systematic reviews/Meta-analysis and 11 pharmacoeconomic studies.In terms of effectiveness,compared with chemotherapy alone,sugemalimab combined with chemotherapy significantly improved progression-free survival(PFS),overall survival(OS),and objective response rate(ORR)in patients with NSCLC.In terms of safety,compared with chemotherapy alone,sugemalimab combined chemotherapy had higher incidence of overall adverse events,but it had a better safety profile compared to other immune combination therapies.In terms of economy,most studies suggested that compared with chemotherapy alone,sugemalimab combined with chemotherapy was not cost-effective,which may be related to the high price of sugemalimab.However,a few studies indicated that sugemalimab combined with chemotherapy could be cost-effective in specific scenarios.Conclusion Sugemalimab has good efficacy in the first-line treatment of NSCLC,but its safety and economy need to be further studied.
